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Review
Forty-five years after the World Health 
Organization recognized cancer as a world 
health problem by creating the International 
Agency for Research on Cancer (IARC), 
carcino genic exposures in the workplace 
remain a concern. Many known and suspected 
carcinogens are found in today’s workplaces, 
and uncertainties about the health effects of 
exposure to these hazards have delayed regula-
tory action and the search for safer alterna-
tives. In this review we focus primarily on 
chemicals, metals, dusts, and physical agents 
for which there is widespread human expo-
sure, predominantly in occupational settings, 
and we address unresolved questions regarding 
carcino genicity. Most of these agents are in 
IARC Groups 2A and 2B—agents for which 
there is sufficient evidence of carcinogenicity 
in animals but limited evidence for carcino-
genicity in humans.
A project to systematically identify 
data gaps was initiated by the National 
Occupational Research Agenda team of the 
U.S. National Institute for Occupational 
Safety and Health (NIOSH) to enhance 
occupational cancer research and involved 
joint planning with IARC, the American 
Cancer Society, the U.S. National Institute of 
Environmental Health Sciences, and the U.S. 
National Cancer Institute. In this review we 
present the results of this effort and identify 
opportunities for further research that would 
resolve classification uncertainties for selected 
high-priority agents. The process included 
a meeting to identify high-priority agents; 
expert reviews of each agent to update the 
literature since the last Monograph evalua-
tion and to identify research priorities; and 
a workshop to discuss the identified data 
gaps and approaches. Expert reviewers were 
selected by the planning committee based on 
expertise in epidemiology and toxicology and 
on knowledge of the agents. For many agents, 
we recognized that opportunities for cohort 
studies would be limited, and reviewers were 
encouraged to consider possible experimen-
tal studies to elucidate carcinogenic mecha-
nisms and molecular epidemiologic studies 
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Objectives: There are some common occupational agents and exposure circumstances for which 
evidence of carcinogenicity is substantial but not yet conclusive for humans. Our objectives were to 
identify research gaps and needs for 20 agents prioritized for review based on evidence of widespread 
human exposures and potential carcinogenicity in animals or humans.
Data sOurces: For each chemical agent (or category of agents), a systematic review was conducted 
of new data published since the most recent pertinent International Agency for Research on Cancer 
(IARC) Monograph meeting on that agent.
Data extractiOn: Reviewers were charged with identifying data gaps and general and specific 
approaches to address them, focusing on research that would be important in resolving classification 
uncertainties. An expert meeting brought reviewers together to discuss each agent and the identified 
data gaps and approaches.
Data synthesis: Several overarching issues were identified that pertained to multiple agents; these 
included the importance of recognizing that carcinogenic agents can act through multiple toxicity 
pathways and mechanisms, including epigenetic mechanisms, oxidative stress, and immuno- and 
hormonal modulation.
cOnclusiOns: Studies in occupational populations provide important opportunities to understand 
the mechanisms through which exogenous agents cause cancer and intervene to prevent human 
exposure and/or prevent or detect cancer among those already exposed. Scientific developments are 
likely to increase the challenges and complexities of carcinogen testing and evaluation in the future, 
and epidemiologic studies will be particularly critical to inform carcinogen classification and risk 
assessment processes.
Key wOrDs: animal, carcinogen, carcinogenesis, epidemiology, human, IARC, mechanisms of 
carcinogenicity, occupational. Environ Health Perspect 118:1355–1362 (2010). doi:10.1289/
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to develop intermediate biomarker data that 
could be used in classification.
Full reviews and recommendations will be 
published in an IARC technical report. Here, 
we summarize recommendations for each of 
the agents and address some over arching topics 
pertaining to several agents or categories of 
agents.
Overarching Topics
Carcinogenic mechanisms. Most tumors arise 
from multiple genetic and epigenetic changes, 
many of which are difficult to measure in vivo 
in experimental animals or humans. Genetic 
changes can be broadly defined to involve 
either inherited or somatic changes in the DNA 
sequence. Epigenetic modifications generally 
involve modification (e.g., by methyla tion or 
acetylation) of DNA or histones in chroma-
tin or the binding of microRNAs (non coding 
RNAs 21–23 bases) to homolo gous sequences 
in mRNA, resulting in a double-stranded 
structure that can decrease production of the 
corresponding protein (Garzon et al. 2009; 
Mathews et al. 2009). Recent advances in can-
cer biology support the view that carcinogenic 
agents can act through multiple toxicity path-
ways and mechanisms, including both genetic 
and epi genetic changes. Alterations in gene 
expression and levels of key proteins are consid-
ered an essential component of the mechanisms 
by which most tumors arise (Croce 2009; Jones 
and Baylin 2007). Although standard methods 
for detecting agents that cause mutation have 
been in place for decades, no standardized, 
validated assays are available for routine assess-
ments for epi genetic events.
“Omics,” the study of large sets of biologi-
cal molecules, is an emerging tool to study 
genetic and epigenetic events related to spe-
cific exposures. Although the number of 
omic techniques is ever expanding, the most 
developed techniques are high-throughput 
DNA sequencing, transcriptomics (studying 
gene expression), epigenomics (studying epi-
genetic regulation of gene expression), pro-
teomics (studying large sets of proteins; the 
proteome), and metabolomics (studying large 
sets of metabolites; the metabolome). Omic 
technologies can be used to study the effects 
of the same chemicals in experimental ani-
mals and in human cells in vitro, eventually 
allowing for a more comprehensive human 
carcino genicity and assessment of carcino-
genic mecha nisms. A broad all-encompassing 
approach is needed that uses the same technol-
ogies in experimental animals, human cells in 
culture, and human populations. Eventually, 
a bio informatics database of human responses 
to different chemical exposures and associated 
chronic diseases could be used to compare 
the effects of novel chemicals with those of 
established carcinogens. Given the sensitiv-
ity of omic analyses, low-dose adverse effects 
could also be observed and distinguished from 
high-dose phenomena, and if exposures were 
accurately assessed, dose–response data could 
be incorporated into risk assessments.
Oxidative stress has been invoked as a 
mechanism in the carcinogenicity of a number 
of agents, including some metals and particles. 
Oxidative damage to cellular DNA, the epi-
genome (including proteins), and lipids can 
occur when reactive oxygen species (ROS) 
escape cell anti oxidant and repair mecha nisms 
(Mayne 2003; Shi et al. 2004; Valavanidis et al. 
2009). Proposed carcinogenic mechanisms 
include direct geno toxicity as well as tumor 
promotion (e.g., arsenic and perhaps other met-
als are thought to promote tumors by causing 
oxidative stress that interferes with apoptosis) 
(Shi et al. 2004). Several methodologic issues 
present challenges to validation of oxidative 
stress biomarker assays, including highly vari-
able background levels of specific DNA lesions 
(e.g., between individuals and between experi-
ments) and the need to consider biomarkers of 
nitration as well as oxidation (Mayne 2003). 
Research is needed to examine the relationship 
between exposure to toxic agents and oxidative 
stress biomarkers and between these biomark-
ers and risk of cancer, while controlling for the 
many individual factors that contribute to oxi-
dative stress. Guidelines on standardizing the 
collection and measurement of oxidative stress 
biomarkers in humans (American Thoracic 
Society 1999; Horvath et al. 2005) are impor-
tant to facilitate their effective use.
Immunomodulation is also associated 
with cancer in humans and plays a particu larly 
important role for some lymphomas (Hartge 
et al. 2006) and other cancers. Although bio-
logical markers measured in blood are avail-
able to assess clinically significant immune 
dysfunction, identification and standardiza-
tion of biomarkers of more subtle changes in 
immune status in humans with specific expo-
sures is complicated by the enormous variety 
of markers and assays and the high level of 
intra individual and inter individual variability 
due, in part, to the inherently dynamic role of 
the immune system. Several agents discussed 
here [e.g., polychlorinated biphenyls (PCBs)] 
have been associated with lymphomas, and 
investigation of their immuno modulatory 
effects may clarify their carcinogenic potential.
Addressing the role of genetic susceptibil-
ity to carcinogenic exposures is also impor-
tant; however, the stable and reproducible 
associations are few. Examining genetic poly-
morphisms related to carcinogen metabolism 
and/or DNA repair may facilitate identifica-
tion of higher cancer risks in susceptible sub-
groups and clarify the role of specific agents in 
mixed exposures. However, the magnitude of 
such associations may be modest and involve 
multiple genes or metabolic pathways, making 
them difficult to detect.
Issues in exposure assessment. Some 
agents considered in this review may occur 
as extremely small particles with at least one 
dimension between 1 and 100 per unit mass 
than larger particles of the same composition, 
and the smaller particles appear to be more 
biologically reactive, toxic, and carcinogenic 
than larger-size particles. Thus, their toxic 
effects may need to be evaluated separately 
from larger particles of the same chemical 
composition (Schulte et al. 2009). Critical 
exposure metrics that should be included are 
particle count, surface area, mass, and density. 
Other physical and chemical properties can 
influence the biological activity and toxicity 
of nano particles, including contaminants and 
the degree of agglomeration (Schulte et al. 
2009). Use of several agents we consider to be 
nanoparticles is increasing, including nano-
titanium dioxide (TiO2), in products.
In occupational settings where many 
Group 2 carcinogens are used, levels of expo-
sure may be relatively low and potential for 
multiple exposures high. High-quality expo-
sure assessment will be required to assess 
quantitative exposure response for specific 
agents while accounting for other potentially 
carcinogenic exposures. Historical monitoring 
data, when available, may be used to create a 
job-exposure matrix. Biomarkers of exposure 
to agents with long biological half-lives, such 
as serum levels of PCBs (Burns et al. 2008), 
may be useful in assessing historical exposures, 
whereas biomarkers of internal dose, such as 
hemo globin adducts, may be useful to charac-
terize recent exposures (Angerer et al. 2007). 
Biomarkers of effects related to carcino-
genicity, such as DNA adducts in urothelial 
cells (Zhou et al. 1997) and chromosomal 
aberrations in peripheral lymphocytes (Yong 
et al. 2009), are useful when population size, 
latency, and/or lack of historical data preclude 
study of traditional epidemiologic end points.
Study design. Some agents discussed 
here are used primarily in small businesses 
with high turnover, where it is difficult to 
assemble large study populations. Alternative 
approaches include use of union records, 
national census records, or records of indi-
viduals licensed to perform certain work (e.g., 
certified pesticide applicators), case–control 
studies with enhanced exposure assessment, 
and cross-sectional surveys examining inter-
mediate markers. It may be possible to recruit 
participants outside of the workplace through 
the media and then use a validated biomarker 
to confirm and quantify recent exposure.
Epidemiologic studies using death certifi-
cates may fail to identify excesses in cancer 
sites with high survival rates or excesses in 
specific morphologic types of cancer. The 
ability to study cancer incidence rather than 
mortality—linking occupational cohorts with 
regional or national cancer registries—would 
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improve detection of cancers with high sur-
vival rates, the accuracy of diagnostic infor-
mation, and more timely identification of 
carcinogenic hazards. In several Nordic coun-
tries, national cancer registries that are linked 
to census occupational data (and in Norway 
to a serum bank) have been an important 
resource for studies of occupational and envi-
ronmental exposures. Such resources could be 
developed in other countries.
Interpretation of evidence for excesses 
in lympho hemato poietic cancers (LHC) 
for several agents has been complicated by 
inconsistencies in specific tumor sites. These 
differences may result from inaccuracy of 
death certificate diagnosis as well as from 
changes in LHC classification and grouping 
over time. Epidemiologic and animal studies 
may consider morphologically distinct hema-
to logic cancers as separate end points, even 
though they may share common cellular ori-
gins. As knowledge of hematologic malig-
nancies evolves, it is important to reexamine 
approaches to disease categorization in epi-
demiology and animal toxicology. Over time, 
there has been growing recognition of close 
relationships and overlap of such morpho-
logically diverse disorders as chronic lympho-
cytic leukemia and multiple myeloma, now 
considered subclassifications of mature B-cell 
neoplasms (Swerdlow et al. 2008).
Data gaps and research priorities for specific 
agents. The agents, exposure circumstances, 
and prior IARC Monograph evaluations of the 
agents considered are listed in the Supplemental 
Material (doi:10.1289/ehp.0901828).
Lead and lead compounds. Although the 
occurrence of lead in the environment has 
decreased greatly because of the elimi na tion 
of most leaded gasoline, substantial occupa-
tional exposures continue primarily via lead 
in the battery industry and lead pigments in 
paints (IARC 2006c). Evidence for carcino-
genicity in workers exposed to inorganic lead 
is most consistent for stomach cancer (rate 
ratio, 1.3–1.5), with lung, kidney, and brain 
cancer showing elevation in some but not 
all studies (IARC 2006c). Background rates 
of stomach cancer are highly variable; there-
fore, epidemiologic studies should consider 
local referent rates and internal dose–response 
analyses. Additional studies of new cohorts 
with well-documented lead exposure, as 
well as further follow-up of existing cohorts, 
would be useful. A study of the NIOSH 
Adult Blood Lead Exposure Surveillance 
(ABLES) registry—which includes 50,000 
workers with at least one blood lead measure-
ment during 1990–2007—is currently under 
way. Future studies could be strengthened 
by including a) assessment of the correlation 
of blood lead measurements with cumula-
tive exposure as measured by bone lead; 
b) assessment of whether Helicobacter pylori 
infection is associated with higher blood lead 
levels; and c) evaluation of genetic suscepti-
bility factors, such as polymorphisms in the 
δ-aminolevulinate dehydratase (ALAD) gene. 
Further experimental research is needed to 
evaluate the mechanisms by which lead may 
cause cancer, with particular emphasis on oxi-
dative stress/apoptosis and the roles of cellu lar 
defense mechanisms, signaling pathways, and 
intra cellular lead-binding patterns.
Indium phosphide and other indium com-
pounds. Intratracheal installation of indium 
phosphide causes pulmonary inflammation and 
high incidences of lung tumors in experimen-
tal animals (IARC 2006b). No epidemiologic 
studies have evaluated indium compounds spe-
cifically for cancer. Studies of workers in the 
U.S. semi conductor industry are unlikely to 
be informative because of limited historical 
exposure, multiple exposures in wafer fabrica-
tion, and little historical exposure-monitoring 
information. Epidemiologic studies, if feasible, 
may be most informative in secondary indi-
um-refining industries (primary refining likely 
results in lower indium and higher cadmium 
exposure). Recent findings of pulmonary 
effects among indium workers in Asia (Chonan 
et al. 2007; Hamaguchi et al. 2008) should 
be investigated further. Concurrent studies of 
exposure and biomarkers of genetic damage, 
such as chromosomal aberrations in accessible 
cells of exposed workers (e.g., nasal epithelium, 
buccal cells, shed urinary cells, or circulating 
lympho cytes), may be useful. Further experi-
mental research should investigate mechanisms 
of indium compound–induced toxicity and 
carcino genicity, with particular focus on oxida-
tive stress, inhibition of protective protein syn-
thetic mechanisms, and DNA damage.
Metallic cobalt (with or without tungsten 
carbide). The evidence for carcinogenicity of 
cobalt with tungsten carbide in humans comes 
from studies finding increased lung cancer risks 
among workers in the hard-metal industry in 
France and Sweden (IARC 2006d). The preva-
lence of such exposures is increasing (Busch 
et al. 2010). There is good experimental evi-
dence that cobalt and cobalt with tungsten 
carbide produce cellular toxicity via formation 
of ROS, leading to oxidative stress and trigger-
ing a number of cellular regulatory pathways 
(Fenoglio et al. 2008). Research recommenda-
tions include updating the French and Swedish 
studies and studying additional cohorts of 
hard-metal manufacturing workers; these stud-
ies should include assessment of molecular bio-
markers of early cellular effects and genetic 
polymorphisms associated with cellular protec-
tive systems. Further research is needed into 
the toxicity of exposure to cobalt with tungsten 
carbide in the nanoparticle size range.
Welding. Epidemiologic studies indicate a 
20–40% increased risk of lung cancer among 
welders (Ambroise et al. 2006; Siew et al. 
2008). Experimental studies are suggestive—
but not conclusive—of lung carcinogenicity 
of welding-fume exposure (Antonini 2003; 
Zeidler-Erdely et al. 2008). Many in vitro 
and in vivo studies have shown welding 
fumes to be geno toxic (Antonini et al. 2003). 
Pulmonary effects consistent with oxidative 
stress and inflammatory responses have been 
observed in experimental animals. Genotoxic 
effects observed in welders include elevated 
8-hydroxydeoxyguanine in urine; DNA–
protein cross links, sister chromatid exchanges, 
and increased micro nuclei in lympho cytes; 
increased DNA strand breaks, chromosome 
aberrations, and increased micronuclei in 
buccal epithelial cells (Antonini et al. 2003; 
Danadevi et al. 2004). Research needs include 
reexamination of existing cohorts and estab-
lishing new cohorts with improved exposure 
assessment (e.g., the type of welding process, 
the type of metal being welded, the types of 
rods and fluxes used, and other characteristics 
of the welding environment such as abrasives, 
cleaners, and degreasers used, and if feasible, 
biomarkers of exposure to manganese or iron) 
and improved smoking data. Experimental 
studies are needed on inhalation exposure to 
different types of welding fumes, including 
ultrafine/nano-size particles, and on epi genetic 
mechanisms, gene expression pathways, and 
functional level changes related to welding 
fume exposure (Rim et al. 2007; Salnikow 
and Zhitkovich 2008). In addition, welders 
have an increased risk of ocular melanoma 
(El Ghissassi et al. 2009). Further research is 
needed to determine whether this is due to 
ultra violet radiation, other forms of electro-
magnetic radiation, or metal and chemical 
fumes emitted during welding.
TiO2. Elevated lung tumor rates have 
been observed in rats after chronic inhala-
tion or intratracheal administration of TiO2 
(Baan et al. 2006). A consistent dose–response 
relation ship for either pulmonary inflamma-
tion or lung tumor response was observed for 
fine and ultrafine TiO2 particle sizes when 
dose was expressed as the particle surface area 
retained in rat lungs (Dankovic et al. 2007). 
These data include doses associated with the 
overloading of rat lung particle clearance, 
which occurs at lower mass doses for ultra-
fine TiO2 than for fine-sized TiO2, and is 
related to the increased surface area of the 
ultrafine particles. Lung overload is associ-
ated with persistent pulmonary inflammation, 
ROS, cell injury and proliferation, and fibro-
sis in rats and mice; and with gene mutation 
and lung tumors in rats. Qualitatively similar 
lung responses, including reduced lung clear-
ance, pulmonary inflammation, and fibrosis, 
have been observed in workers in dusty jobs, 
although elevated lung tumors have not been 
observed in epidemiologic studies of TiO2 
workers (Baan et al. 2006).
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Recent subchronic studies in rats confirm 
earlier findings that particle size (as well as crys-
tal structure) and coatings can influence pul-
monary responses (inflammation, cyto toxicity, 
and cell proliferation) to TiO2 (Sager et al. 
2008; Sager and Castranova 2009; Warheit 
et al. 2006, 2007) and suggest that inhaled 
TiO2 may act through a secondary genotoxic 
mechanism involving chronic inflammation 
and oxidative stress related to particle surface 
area (Schins and Knaapen 2007). The observa-
tion of inhaled discrete nanoscale TiO2 parti-
cles inside rat alveolar epithelial cell organelles, 
including the nucleus (Geiser et al. 2005), 
suggests that direct geno toxic mechanisms 
are also possible (Schins and Knaapen 2007). 
Epidemiologic studies with well-characterized 
exposures and adequate follow-up are needed, 
especially for workers producing or using nano-
scale TiO2. Possible cohorts include workers 
in industries using nano scale TiO2, such as 
the cosmetic industry. Given increasing appli-
cations of nano-TiO2 in consumer products, 
there is a need to develop better techniques to 
detect TiO2 in tissues and to examine possible 
carcinogenicity of nano-TiO2 by other routes 
of exposure (e.g., oral, dermal).
Diesel engine exhaust. Two meta-analyses 
estimated the summary risk for lung can-
cer and diesel engine exhaust (DE) exposure 
to range from 1.33 [95% confidence inter-
val (CI), 1.24–1.44] (Bhatia et al. 1998) 
to 1.47 (95% CI, 1.29–1.67) (Lipsett and 
Campleman 1999); only a few studies have 
included retro spective exposure assessment 
(Garshick et al. 2008; Neumeyer-Gromen 
et al. 2009; Steenland et al. 1990). Two stud-
ies nearing completion will provide informa-
tion on quantitative exposure–response data 
based on historical exposure estimates. These 
include a cohort and nested case–control study 
of lung cancer in U.S. non metal miners with a 
wide range of DE exposure (National Research 
Council and Institute of Medicine 2008) and 
additional retrospective exposure assessment 
in a truck driver cohort with light-to-moderate 
DE exposure (Garshick E, personal commu-
nication). If the research demonstrates expo-
sure response, it will be important to identify 
the under lying mechanisms of DE-induced 
carcinogenesis and identify the components 
of DE that are most biologically active in 
humans. DNA adducts formed by nitro-
polycyclic aromatic hydro carbons (PAHs) and 
PAHs in animal and cellular studies have been 
well documented. These and other biomarkers 
could be incorporated in cross-sectional epide-
miologic studies of DE exposure and biomark-
ers of inflammation, genotoxicity, and other 
rele vant early biological effects.
Refractory ceramic fibers. Refractory 
ceramic fibers (RCF), which have replaced 
asbestos as high-temperature insulation, induce 
benign and malignant lung tumors in rats 
(Mast et al. 1995). Only one small U.S. occu-
pational cohort exposed to these bio persistent 
fibers has been studied; at last follow-up, there 
were only nine lung cancer deaths (LeMasters 
et al. 2003). A European study found an expo-
sure-related excess of pleural plaques after con-
trolling for past asbestos exposure (Cowie et al. 
2001). Identification and follow-up of new 
and established U.S. and European cohorts 
would be useful. Animal research has not been 
conducted on the combined effects of RCF 
and granular, low-biosoluble particles such as 
TiO2, which can aggravate effects of inhaled 
fibers. The impact of fiber length on carcino-
genicity should also be investigated.
The validity of negative dose–response 
data in rats after inhalation exposure to RCF 
is questionable because there are indications 
that the sensitivity of the rat inhalation model 
with man-made fibers is relatively low (Muhle 
and Pott 2000; Wardenbach et al. 2005). 
Future research in developing a sensitive rat 
inhalation model for RCF is needed.
Carbon black. Sorahan and Harrington 
(2007) reported elevated lung cancer in an 
update of the U.K. carbon worker cohort 
standardized mortality ratio, 1.46; 95% CI, 
1.13–1.85), with some analyses suggesting that 
carbon black may be a late-stage carcinogen. 
No new chronic studies in animals have been 
published since the IARC Monograph (Baan 
et al. 2006). Several recent sub chronic stud-
ies in rats and mice (Duffin et al. 2007; Sager 
and Castranova 2009; Stoeger et al. 2006) 
have shown that particle size and surface area 
dose of carbon black and other poorly soluble 
particles influence the pulmonary inflamma-
tion response, considered key in the pathway 
to particle-induced lung cancer in rats (Schins 
and Knaapen 2007). Research needs include 
updating epidemiology cohorts with data 
on work histories and exposures in relation 
to particle size and surface area, and recruit-
ment of additional carbon black facilities. The 
relation ship between occupational exposure 
to carbon black and validated biomarkers 
of oxidative stress should be examined and 
exposure– response relationships in humans 
and rodents quantified, including the role of 
particle size.
Styrene and styrene-7,8-oxide. In 2008, 
a U.S. National Toxicology Program (NTP) 
expert panel reviewed styrene, finding lim-
ited evidence in humans but sufficient evi-
dence of animal carcinogenicity from multiple 
studies in mice by multiple routes (Styrene 
Expert Panel 2008). Epidemiologic studies 
of styrene in the styrene–butadiene rubber 
industry have been limited by multiple expo-
sures, a limitation partially addressed by retro-
spective exposure assessment (Sathiakumar 
et al. 2005). Studies in the fiberglass boat– 
building industry have been limited by small 
size and short duration of exposure (Ruder 
et al. 2004). Interpretation of the epidemio-
logic evidence is complicated by findings of 
higher risk in less-exposed cohorts, variation 
in high-LHC sites in different studies, and 
inconsistency in findings for pancreatic can-
cer. At least 70 publications released since 
the styrene monograph (IARC 2002) explore 
various mechanistic aspects of potential 
carcinogenicity in humans and rodents. 
Recommendations for new research include 
pooled analyses of human studies on chromo-
some aberrations and other genotoxic effects 
and updating the existing epidemiologic stud-
ies with particular attention to the accurate 
diagnosis and classi fi ca tion of LHCs.
Propylene oxide. Since the last IARC 
review (IARC 1994), only one epidemiologic 
study of U.S. propylene oxide (PO) manu-
facturing workers has been published (Olsen 
et al. 1997); the authors did not find increased 
mortality due to cancer by duration of expo-
sure with or without latency, nor did they 
find increased cancer risk by process (PO vs. 
ethylene oxide). Recent exposure and biomarker 
studies have shown that PO forms chemically 
stable hemo globin and DNA adducts and that 
concentrations of these adducts are related lin-
early to air concentrations of PO (Boogaard 
et al. 1999); in addition, Czene et al. (2002) 
reported that hemoglobin and DNA adducts 
and sister chromatic exchanges were increased 
significantly in workers occupationally exposed 
to PO. Potential cohorts for future epidemio-
logic studies exist in a number of industries and 
countries; occupational study cohorts should 
include women, if possible, because PO might 
be a mammary carcinogen (Rudel et al. 2007).
Formaldehyde. Formaldehyde has been 
classified by IARC as a Group 1 carcino-
gen based on sufficient evidence for naso-
pharyngeal cancer in humans (Baan et al. 
2009; IARC 2006a). Both IARC and the NTP 
scientific review panel have recently supported 
a causal relation between formaldehyde and 
acute myeloid leukemia based on new research 
findings (Baan et al. 2009; Beane Freeman 
et al. 2009; Formaldehyde Expert Panel 2009; 
Zhang et al. 2009); however, more research is 
needed to elucidate the mechanism by which 
formaldehyde could cause myeloid leukemia in 
humans. Mechanisms through which inhaled 
formaldehyde may cause leukemia should be 
explored further, including exposure to cir-
culating blood or stem cells in the nose and 
pathways by which inhaled formaldehyde or 
formaldehyde-derived intermediates can reach 
bone marrow or lymphatic tissue. Follow-up 
of existing occupational cohorts should con-
tinue, with registry linkage to identify incident 
cancers and attention to appropriate classifica-
tion and grouping of LHCs. Additional stud-
ies of the genotoxic and hematologic effects 
of formaldehyde exposure in occupational 
cohorts and in experimental animals would 
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be useful, and such studies should incorporate 
sensitive biological markers of internal dose.
Acetaldehyde. Acetaldehyde is the first 
metabolite of ethanol oxidation. It binds to 
DNA, forming stable DNA adducts that 
are observed in alcohol consumers (Seitz 
and Stickel 2007). Numerous epidemio-
logic studies in alcohol drinkers with alcohol 
dehydrogenase (ALDH2) deficiency or low 
aldehyde dehydrogenase (ADH1B) activity 
(Lachenmeier et al. 2009; Salaspuro 2009) 
provide the most compelling evidence for 
the carcinogenicity of acetaldehyde. A recent 
large-scale case–control study reported a 
multi plicative combined risk for esopha geal 
cancer among alcohol and tobacco consumers 
who were low ADH1B and ALDH2-deficient 
carriers (OR = 382.3; 95% CI, 47.4–3084.9 
for those drinking > 30 g/day) (Lee et al. 
2008). These studies strongly suggest that 
acetaldehyde derived from the metabolism of 
ethanol contributes to upper digestive tract 
cancers. The accumulated scientific evidence 
warrants a new evaluation of acetaldehyde by 
IARC. Exposures to acetaldehyde in occu-
pational settings should be characterized 
and the potential for conducting epidemio-
logic studies explored. These studies should 
consider all potential sources of exposure to 
acetaldehyde and the extent to which genetic 
poly morphisms influence carcinogenic risks. 
Studies in the flavoring industry may be of 
particular interest.
Trichloroethylene (TCE). Since the IARC 
review (IARC 1995b), numerous publica-
tions have evaluated associations between 
TCE exposure in humans and cancers at 
several sites, including kidney and liver can-
cer, and non-Hodgkin lymphoma (NHL). 
Meta-analyses would be useful because indi-
vidual studies have limited statistical power 
for these relatively uncommon cancer sites. 
Additional studies of cancer incidence and 
mortality in new cohorts without multiple 
solvent exposures (e.g., those using TCE for 
a final degreasing after assembly-line produc-
tion of kitchen utensils) would be beneficial. 
Research is needed to determine which TCE 
metabolites are the agents of carcinogenesis for 
specific sites. Studies of effects of TCE expo-
sure on cell-signaling pathways and epigenetic 
changes induced by TCE and its metabolites 
would help in determining potential mecha-
nisms of carcinogenicity. TCE is metabolized 
by the cytochrome P450 (CYP) pathway to 
oxidative metabolites and by the glutathione 
(GSH) conjugation pathway to genotoxic 
metabolites; incorporation of data on genetic 
polymorphisms in glutathione S-transferase 
and CYP2E1 would be useful in this regard.
Tetrachloroethylene (Perc). Since the 
IARC review (IARC 1995a), several human 
epidemiologic studies have reported associa-
tions between Perc exposure and esophageal 
cancer and NHL, with some evidence for 
breast, urinary bladder, and kidney cancer 
(Ruder 2006). Although many industries 
use Perc, the chief venue of Perc exposure 
is dry-cleaning shops, which generally have 
< 10 employees (Gold et al. 2008). Further 
studies in this industry could be facilitated 
by using exhaled-breath specimens for study 
inclusion and exposure assessment (McKernan 
et al. 2008). Two U.S. dry-cleaning cohorts 
could be pooled for mortality and cancer inci-
dence studies (Blair et al. 2003; Ruder et al. 
2001), and additional cohorts of workers out-
side the United States and Europe should be 
identified. A major research gap is that mecha-
nisms of carcinogenicity are not characterized 
sufficiently or tested; studies are needed that 
evaluate the genotoxic and oxidative poten-
tial of alternative metabolic pathways. Last, 
adequate physiologically based pharmaco-
kinetic (PBPK) models should be developed 
that allow for prediction of metabolism and 
difference in metabolism between species for 
a number of key metabolites to aid in the 
identification of sensitive subpopulations and 
target organs for a carcino genic response.
Methylene chloride [dichloromethane 
(DCM)]. Inhalation exposure to DCM causes 
lung and liver tumors in mice and mammary 
tumors in rats (IARC 1999b). Epidemiologic 
case–control and cohort studies have found 
positive, but inconsistent, associations for 
cancers of a number of sites. Based on animal 
and epidemiologic studies to date, sites of 
particular interest for future studies include 
brain, breast, and the lympho hemato poietic 
system. Available epidemiologic studies 
of DCM are limited by small numbers of 
exposed cases, few women enrolled, and poor 
exposure assessments. The major research 
need is the identification of new large cohorts 
with adequate numbers of women and robust 
exposure assessment using current and retro-
spective department-specific exposure or 
biological markers. In addition to identify-
ing larger cohorts of film and textile work-
ers, some potential new occupations include 
workers in furniture stripping or automobile 
body repair shops. Urinary DCM has been 
shown to correlate with air measurements 
(Imbriani and Ghittori 2005), and studies 
are needed to develop and evaluate urinary 
DCM measure ments for use in exposure 
assessment. Recent mechanistic studies have 
questioned the role of the GSH pathway in 
toxicity (Landi et al. 2003; Watanabe and 
Guengerich 2006; Watanabe et al. 2007). 
DCM has been reported to be mutagenic in 
bacteria without activation (IARC 1999b). 
Clearly, research is needed with regard to 
the metabolites involved and the mecha-
nism of carcinogenicity of DCM-induced 
rodent tumors, especially in the context of 
informing human risk. Before accurate PBPK 
models can be developed, the metabo lism and 
metabo lites responsible for toxicity at specific 
targets should be investigated.
Chloroform ( t r i ch loromethane) . 
Chloroform causes cancer in rats and mice, 
most likely through a mechanism involving 
cyto toxicity (Schoeny et al. 2006), and there is 
weak evidence for the genotoxicity of chloro-
form (IARC 1999a). Exposure to chloro form 
is primarily through drinking water and swim-
ming pool water; thus, the epidemiology is 
based on exposure to this complex mixture 
and not to chloroform per se. Since the last 
IARC evaluation (IARC 1999a), several epi-
demiologic studies have been published on the 
association between exposure to chloro form 
in disinfection by-products (DBPs) and risk 
of bladder cancer, including a pooled analysis 
of previous case–control studies (Villanueva 
et al. 2004) and a new case–control study 
from Spain (Villanueva et al. 2007). However, 
drinking water with high levels of chloro-
form also contains high levels of other tri-
halo methanes (THMs) and other DBPs, and 
bladder cancer associated with drinking water 
may result from dermal/inhalation exposure 
to the brominated THMs or DBPs other 
than chloro form. Future IARC evaluations 
should address the entire group of DBPs in 
drinking water. Exposures to chloroform and 
other DBPs may be higher from showering, 
bathing, or swimming than from oral expo-
sure to drinking water. Other THMs/DBPs 
should be evaluated for biological effects in 
rodents via the dermal and/or inhalation route. 
Epidemiologic case–control studies should 
incorporate information on route of exposure 
and detailed DBP exposure assessment, as well 
as pooling information from multiple studies 
and countries, where feasible. Epidemiologic 
studies are warranted for high-exposure groups 
such as competitive swimmers and indoor 
pool attendants/lifeguards. There should also 
be follow-up of cohorts of medical personnel 
exposed to chloroform when chloroform was 
used as an anesthetic gas.
PCBs. Identifying research gaps for PCBs 
is considerably more difficult, because a large 
volume of epidemiologic and mechanistic 
data has been published since the last IARC 
evaluation (IARC 1987). Moreover, mix-
tures of PCBs associated with occupational 
and environmental exposure have changed 
over time and vary across the occupational 
and population groups studied. In addition, 
environmental and metabolic processes sub-
stantially alter the composition of PCB mix-
tures in the environment and in the body. 
As a result, residual PCBs in the environ-
ment involve altered mixtures differing in 
composition—and possibly more toxic and 
persistent—than the mixtures that were used 
commercially (Cogliano 1998). Among most 
occupational cohorts, dermal and airborne 
Ward et al.
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exposures predominate, whereas among the 
general population, dietary exposures are gen-
erally most significant. Although most studies 
of highly exposed occupational cohorts find 
cancer excesses for specific cancer sites, the sites 
involved have been quite variable. Associations 
between NHL and levels of certain PCB con-
geners in serum have been reported in several 
cohort and case–control studies (Engel et al. 
2007; Rothman et al. 1997), whereas stud-
ies of serum levels of PCBs and breast cancer 
have been inconsistent, although largely nega-
tive (Ward et al. 2000). Additional studies 
within highly exposed populations, including 
an in-progress cancer incidence study within 
the large (> 26,000 workers) NIOSH cohort 
(Prince et al. 2006; Ruder et al. 2006), nested 
case–control studies in this cohort and/or 
occupational cohorts in other countries, and 
analysis of PCB blood levels in cases and con-
trols, might be informative. Mechanisms of 
genotoxicity/carcinogenicity for PCBs appear 
to involve ROS, oxidative stress, oxidative 
DNA damage, and formation of DNA adducts 
(Jeong et al. 2008; Ludewig et al. 2008). More 
research is needed on these mechanisms and 
on cell proliferation, which could also play an 
important role in the induction of mutations 
and subsequent carcino genicity.
Di(2-ethylhexyl) phthalate (DEHP). 
Although extensive human exposure to DEHP 
occurs through its use as a plasticizer of poly-
vinyl chloride (PVC), definitive epidemiologic 
studies are not available because of the dif-
ficulty in identifying highly exposed workers 
in retrospective cohort or case–control studies. 
Since the previous monograph review, which 
concluded that liver cancer in animals resulted 
from induction of peroxi some proliferator-ac-
tivated receptor-α (PPARα) and that peroxi-
some proliferation activation was not relevant 
to humans (IARC 2000), several lines of evi-
dence have suggested that DEHP may have 
multiple mechanisms of carcinogenesis, such 
as induction of cell proliferation, decreased 
apoptosis, and oxidative DNA damage, some 
of which might be relevant to humans (Rusyn 
et al. 2006). The hypothesized PPARα mode 
of action has also been questioned (Guyton 
et al. 2009). A study of DEHP-induced 
tumori genesis in wild-type and PPARα-
null mice found that the incidence of liver 
tumor in PPARα-null mice exposed to 0.05% 
DEHP was higher (25.8%) than that in simi-
larly exposed wild-type mice (10.0%) (Ito 
et al. 2007). Microarray profile studies found 
that patterns of up- or down-regulated genes 
are quite different in hepato cellular adenoma 
tissues of wild-type and PPARα-null mice 
exposed to DEHP (Takashima et al. 2008). 
Animal studies have also suggested additional 
target organs in rats [pancreatic acinar-cell ade-
noma (David et al. 2000) and testicular Leydig 
cell tumors (Voss et al. 2005)]. Future studies 
in mouse models using hPPARαTetOff (which 
expresses the human receptor only in liver) 
or hPPARαPAC (which expresses the human 
receptor in liver, kidney, heart, intestine, and 
brown adipose tissues) may elucidate the role 
of human PPARα in DEHP carcinogenesis. 
Further characterization of DEHP exposures 
in industry is needed and could be carried 
out in established cohorts in PVC-processing 
factories using mono-2-ethylhexyl phthalate 
and mono(2-ethyl-5-carboxypentyl) phthalate 
as sensitive and specific biomarkers of DEHP 
exposure.
Atrazine. Schoeny et al. (2006) reported 
that atrazine caused mammary gland tumors 
in Sprague-Dawley rats through accelerated 
aging within the brain–pituitary–ovarian axis 
(i.e., constant estrus); however, they found 
that it was not carcino genic in F344 rats or 
via the diet in CD-1 mice, but it did cause 
lymphomas via intra peritoneal injection in 
CD-1 mice. Although the mechanism by 
which atrazine causes mammary tumors in 
Sprague-Dawley rats may not be relevant to 
humans (Schoeny et al. 2006), additional 
studies would help to clarify the situation. 
For example, does atrazine interfere with the 
hypothalamic–pituitary–ovarian axis or alter 
the secretion of luteinizing hormone and pro-
lactin in humans? More extensive micro array 
and proteomic studies in rodents and humans 
would help to characterize the pathways dis-
rupted by atrazine. Studies should also inves-
tigate the ability of atrazine to alter immune 
function and aromatase in species relevant 
to humans, as well as in human molecular 
epidemiology studies. Several studies have 
found non significant associations between 
atrazine exposure and NHL; for example, a 
study of 36,513 atrazine-exposed pesticide 
applicators in the U.S. Agricultural Health 
Study (AHS) demon strated non significant 
excesses of lung cancer, bladder cancer, NHL, 
and multiple myeloma (Rusiecki et al. 2004). 
Follow-up of the AHS cohort through 2006 
is now under way and, along with analysis of 
biomarkers among corn farmers and similar 
studies in atrazine-exposed women (Bakke 
et al. 2008; Vermeulen et al. 2005), could 
shed light on the effects of atrazine.
Shift work. Excess incidence of breast can-
cer has been observed consistently in studies of 
women with prolonged exposure to shift work 
involving exposure to light at night (Kolstad 
2008; Stevens 2009). Research needs in this 
area include a) a better definition of what is 
meant by shift work and related exposure met-
rics; b) studies of markers of circadian disrup-
tion in non–day workers; c) better descriptions 
of controls and their exposure to light at night; 
and d) investigation of the effect of variations 
in expression of circadian genes on cancer in 
shift workers. An emerging area of interest is 
the relative toxicity of occupational chemical 
exposure depending on time of day of that 
exposure. The marked circadian variations in 
cell division and DNA repair during the daily 
cycle are controlled by the circadian genes 
(Haus and Smolensky 2006; Stevens et al. 
2007). Therefore, non–day workers may have 
very different susceptibility to occupational 
exposures compared with day workers. Studies 
are also needed to determine if shift work is 
associated with other cancers, especially hor-
monally related cancers, and prostate cancer 
in particular. If further experimental and epi-
demiologic evidence confirms a causal asso-
ciation between exposure to light at night and 
breast cancer, it will be important to develop 
interventions to reduce the risk.
Conclusions
Research gaps and opportunities have been 
identified that can help to resolve uncertain-
ties regarding the carcinogenicity in humans 
of a number of important IARC-classified 
agents. We hope that this process will lead to 
well-planned epidemiologic and mechanistic 
studies for these agents, as well as renewed 
interest and funding for studies of agents for 
which there are substantial or widespread 
occupational and environmental exposures.
Several important scientific develop-
ments are likely to increase the challenges 
and complexities of carcinogen testing and 
evaluation in the future. Use of omics tech-
niques will accelerate the understanding of 
the cellular and molecular basis for biological 
responses to environmental and occupational 
exposures, and high-throughput technolo-
gies will increase the number of agents that 
can be tested. The important role of organ 
and organism-level responses such as inflam-
mation, immuno modulation, and hormonal 
influences, as well as interindividual varia-
tion in susceptibility and genetic repair in 
the carcino genic process, are increasingly 
understood. Therefore, the science of carcino-
gen testing and evaluation must be increas-
ingly multi disciplinary, examining biologic 
responses from the molecular to the organism, 
and using test systems and approaches that 
capture multiple mechanisms and end points.
Most carcino genic mechanisms are not 
simple, and evidence is often too limited to 
conclude lack of relevance to humans. When 
evidence regarding mechanism is considered 
in the up grading or down grading of carcino-
gens, it should be evaluated with the same 
rigor as traditional epidemiologic and bio assay 
data [see, for example, the IARC preamble 
(IARC 2006e) with regard to epidemiologic 
studies, including types of studies to be con-
sidered, quality of studies, role of meta- and 
pooled analyses, and criteria for causality]. 
Epidemiologic studies will be particularly 
critical in evaluating the relationship between 
intermediate biomarkers and cancer risk in 
Research recommendations for 20 carcinogens
Environmental Health Perspectives • volume 118 | number 10 | October 2010 1361
occupational groups or in the general popu-
lation and in investigating genetic suscep-
tibility factors. In the rush to embrace new 
bio technologies in epidemiology, we must not 
lose sight of the tremendous gains in knowl-
edge that have accrued from conventional 
epidemiologic occupational cohort and case–
control studies. We encourage investigators 
to continue to search for study populations in 
which the linkage of work history information 
and mortality or cancer incidence data can be 
informative about the cancer risks of workers 
with different job or industry titles or different 
exposure histories. We also encourage release 
(in de identified form) of completed epide-
miologic studies for reanalysis, as is commonly 
done with government-funded studies in the 
United States.
In this review we discuss only a small 
fraction of potentially carcinogenic agents—
generally those for which there is substantial 
evidence for animal carcino genicity but as 
yet inconclusive evidence of human carcino-
genicity. For most other agents, there exists 
little or no evidence by which to evaluate 
animal or human carcino genicity because 
neither adequately designed animal bio assays 
nor human studies have been done. However, 
even the modest research agenda outlined 
here will be difficult to achieve given cur-
rent trends. Although objective evaluation 
of trends in research funding and produc-
tivity related to environmental/occupational 
risk factors for cancer is difficult, there is a 
general sense that funding for occupational 
cancer research has declined over the past 
two decades and that fewer and fewer epide-
miologists, exposure assessment experts, and 
toxicologists are attracted to careers in this 
area. A more formal evalua tion of these trends 
could consider what measures could encour-
age a) renewed interest in this field; b) train-
ing, career, and funding opportunities; and 
c) advances in addressing legal–ethical barriers 
to accessing worksites, study populations, and 
personal/medical data. If meas ures are not 
taken to stem declines in this area of research, 
we will continue to have an extremely limited 
epidemiologic knowledge base for the evalua-
tion of potential carcino gens.
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